A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs Avexitide (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LUCIDITY
- Sponsors Amylyx Pharmaceuticals
- 24 Dec 2024 Status changed from planning to not yet recruiting.
- 04 Dec 2024 According to an Amylyx Pharmaceuticals, the company will present the trial design at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles on December 12-14, 2024.
- 04 Dec 2024 According to an Amylyx Pharmaceuticals, the trial will be conducted at approximately 20 sites in the U.S.